Gut microbial dysbiosis aggravated Parkinson-like pathology induced by MPTP/probenecid

Area of Science:

• Neuroscience
• Microbiology
• Gastroenterology

Background:

• Parkinson's disease (PD) is a neurodegenerative disorder with motor and non-motor symptoms.
• Gut microbiota (GM) dysbiosis is observed in PD patients, but its causal role is unclear.

Purpose of the Study:

• To investigate the causal relationship between gut microbial dysbiosis and PD pathogenesis.
• To explore the impact of gut microbiota on gastrointestinal (GI) dysfunction, motor deficits, inflammation, and dopaminergic (DAergic) neuronal loss in a PD mouse model.

Main Methods:

• Utilized MPTP/probenecid-induced PD mouse model and antibiotic cocktail (ABX) to induce gut dysbiosis.
• Analyzed fecal microbiota composition using 16S rRNA sequencing.
• Assessed GI and motor functions, inflammation markers, and DAergic neuronal loss.
• Performed fecal microbiota transplantation (FMT) to evaluate its therapeutic effects.

Main Results:

• ABX treatment significantly reduced GM diversity and abundance in PD mice.
• Gut dysbiosis aggravated GI dysfunction, motor deficits, inflammation, and DAergic neuronal loss.
• FMT treatment corrected gut dysbiosis, increased short-chain fatty acids (SCFAs), and improved GI/motor functions.
• FMT also attenuated peripheral and central inflammation in PD mice.

Conclusions:

• Gut microbial dysbiosis exacerbates PD pathological damage.
• Gut microbiota plays a crucial role in PD pathogenesis via the microbiota-gut-brain axis.
• FMT shows therapeutic potential for PD by modulating gut microbiota and mitigating disease progression.